Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
Medical Dialogues11d
Biocon Biologics, Civica join hands to expand Insulin Aspart access in US
Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...
The Pharma Letter12d
Biocon and Civica link up on Insulin Aspart access in USA
Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...
Business Today8d
Biocon Ltd (BIOCON) Share Price
The main industry in which Biocon Ltd operates is Pharmaceuticals - Indian - Bulk Drugs & Formln. Auditor/Auditors for Biocon Ltd is/are BSR & Co LLP. In the main management, Kiran Mazumdar Shaw ...
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
The Victoria Advocate13d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan.It has a pipeline of 12 biosimilar assets under ...
Medical Dialogues10d
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...
Morningstar11d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...